99 related articles for article (PubMed ID: 19567357)
1. Diagnosis and management of hypertension in advanced renal cell carcinoma: prospective evaluation of an algorithm in patients treated with sunitinib.
Bamias A; Lainakis G; Manios E; Koroboki E; Gyftaki R; Zakopoulos N; Dimopoulos MA
J Chemother; 2009 Jun; 21(3):347-50. PubMed ID: 19567357
[TBL] [Abstract][Full Text] [Related]
2. The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer.
Bamias A; Manios E; Karadimou A; Michas F; Lainakis G; Constantinidis C; Deliveliotis C; Zakopoulos N; Dimopoulos MA
Eur J Cancer; 2011 Jul; 47(11):1660-8. PubMed ID: 21549588
[TBL] [Abstract][Full Text] [Related]
3. Home blood-pressure monitoring in patients receiving sunitinib.
Azizi M; Chedid A; Oudard S
N Engl J Med; 2008 Jan; 358(1):95-7. PubMed ID: 18172185
[No Abstract] [Full Text] [Related]
4. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
5. [Treatment with sunitinib and hypothyroidism--a case report and overview of literature].
Kreze A; Stáhalová V; Zadrazilová A; Koskuba J; Kosák M
Klin Onkol; 2009; 22(4):176-8. PubMed ID: 19731880
[TBL] [Abstract][Full Text] [Related]
6. Therapy of Treatment-Related Hypertension in Metastatic Renal-Cell Cancer Patients Receiving Sunitinib.
Ivanyi P; Beutel G; Drewes N; Pirr J; Kielstein JT; Morgan M; Ganser A; Grünwald V
Clin Genitourin Cancer; 2017 Apr; 15(2):280-290.e3. PubMed ID: 27863831
[TBL] [Abstract][Full Text] [Related]
7. Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.
Vickers MM; Heng DY; Hemmelgarn B; Eigl BJ
Clin Genitourin Cancer; 2009 Oct; 7(3):E104-6. PubMed ID: 19815480
[TBL] [Abstract][Full Text] [Related]
8. Management of antiangiogenic therapy-induced hypertension.
de Jesus-Gonzalez N; Robinson E; Moslehi J; Humphreys BD
Hypertension; 2012 Sep; 60(3):607-15. PubMed ID: 22851729
[No Abstract] [Full Text] [Related]
9. Re: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
van den Meiracker AH; Danser AH; Sleijfer S; Kappers MH
J Natl Cancer Inst; 2011 Oct; 103(20):1557; author reply 1558. PubMed ID: 21862728
[No Abstract] [Full Text] [Related]
10. Management of adverse events in patients with metastatic renal cell carcinoma treated with sunitinib and clinical outcomes.
Arakawa-Todo M; Yoshizawa T; Zennami K; Nishikawa G; Kato Y; Kobayashi I; Kajikawa K; Yamada Y; Matsuura K; Tsukiyama I; Saito H; Hasegawa T; Nakamura K; Sumitomo M
Anticancer Res; 2013 Nov; 33(11):5043-50. PubMed ID: 24222148
[TBL] [Abstract][Full Text] [Related]
11. Exfoliative esophagitis in a patient with metastatic renal cell carcinoma during sunitinib treatment.
Huang J; Wang T; Huang Y
Med Oncol; 2013 Mar; 30(1):436. PubMed ID: 23283650
[No Abstract] [Full Text] [Related]
12. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
Tamaskar I; Garcia JA; Elson P; Wood L; Mekhail T; Dreicer R; Rini BI; Bukowski RM
J Urol; 2008 Jan; 179(1):81-6; discussion 86. PubMed ID: 17997441
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib-aggravated hypertension.
Rivera F; Benounna M; Sánchez de la Nieta MD
J Hypertens; 2009 Jul; 27(7):1502-3. PubMed ID: 19542988
[No Abstract] [Full Text] [Related]
14. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.
Wong MK; Jarkowski A
Pharmacotherapy; 2009 Apr; 29(4):473-8. PubMed ID: 19323623
[TBL] [Abstract][Full Text] [Related]
15. Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma.
Bono P; Rautiola J; Utriainen T; Joensuu H
Acta Oncol; 2011 May; 50(4):569-73. PubMed ID: 21208033
[TBL] [Abstract][Full Text] [Related]
16. [Tumor lysis syndrome in a patient with a renal carcinoma treated with sunitinib].
Rodríguez-Reimúndes E; Perazzo F; Vilches AR
Medicina (B Aires); 2011; 71(2):158-60. PubMed ID: 21550933
[TBL] [Abstract][Full Text] [Related]
17. Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate.
Nicholaou T; Wong R; Davis ID
Lancet; 2007 Jun; 369(9577):1923-4. PubMed ID: 17560435
[No Abstract] [Full Text] [Related]
18. Acalculous cholecystitis in a patient with metastatic renal cell carcinoma treated with sunitinib.
Gomez-Abuin G; Karam AA; Mezzadri NA; Bas CA
Clin Genitourin Cancer; 2009 Jan; 7(1):62-3. PubMed ID: 19213671
[TBL] [Abstract][Full Text] [Related]
19. Severe cardiomyopathy in a patient with renal cell carcinoma after treatment with the novel tyrosine kinase inhibitor sunitinib.
Chorianopoulos E; Jäger D; Katus HA; Frey N
Clin Res Cardiol; 2007 Nov; 96(11):829-30. PubMed ID: 17694380
[No Abstract] [Full Text] [Related]
20. Sunitinib-induced acute hemolysis without hypertension: a case report.
Jain R; Mathew P; Wood CG; Tannir NM
Clin Genitourin Cancer; 2008 Sep; 6(2):122-3. PubMed ID: 18824436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
